5 Stocks With Recent Price Strength Amid Wall Street Volatility

CSTL, IDN, PANL, FSRL and PRM are showing sharp price strength amid renewed Wall Street volatility.

Original reporting
Zacks Commentary · Zacks Investment Research
Published Nov 20, 2025, 1:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 21, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
5 Stocks With Recent Price Strength Amid Wall Street Volatility — source image
Decision brief

The 30-second read

$IDNNeutralMed
01

Why it matters

The observed price strength suggests investor confidence in these stocks, potentially signaling sector stability.

02

Market read

While some stocks demonstrate resilience, overall market volatility warrants caution. The stocks with high relevance could influence short-term trading strategies.

03

What to watch

Broader economic indicators and upcoming earnings reports could influence stock trajectories.

Relevance 6/10Timing: Immediate to short-term

Background

The market has experienced increased volatility recently, but select stocks like IDN, PANL, and PRM are showing resilience.

Company-level read

Ticker impact

$IDNNeutralMedium confidence
Context

High relevance due to positive sentiment and recent price strength.

Expected impact

Moderate upward movement expected in the short term.

Evidence & confidence

Price strength coupled with neutral sentiment suggests a possible continuation of upward trend, but market volatility introduces uncertainty.

$PANLBullishMedium confidence
Context

High relevance with somewhat-bullish sentiment indicating potential upside.

Expected impact

Potential for moderate price appreciation over the next few weeks.

Evidence & confidence

Bullish sentiment and recent price strength support a positive outlook, but broader market conditions could influence outcomes.

$PRMNeutralLow confidence
Context

High relevance with neutral sentiment; price strength may reflect short-term momentum.

Expected impact

Likely limited movement; watch for breakout or reversal signals.

Evidence & confidence

Neutral sentiment suggests caution; technical indicators should be monitored for confirmation.

$CSTLNeutralLow confidence
Context

Lower relevance with neutral sentiment; recent price strength is less impactful.

Expected impact

Limited expected movement; focus on other more relevant stocks.

Evidence & confidence

Minimal relevance and neutral sentiment imply limited trading opportunities.

Market effects

Potential positive sentiment in financial markets and energy sectors due to overall market strength.

Limited regional impact; primarily US-focused stocks.

Moderate, as US stocks influence global indices.

Counterpoint

The recent price strength may be a short-term rally without fundamental support, risking a reversal.

Key entities

  • IDN

    A company showing recent price strength amid market volatility.

  • PANL

    A company with a somewhat-bullish outlook amid recent gains.

  • PRM

    A company exhibiting neutral sentiment but recent price strength.

Related articles

$IDNMed

Intellicheck Reports Third Quarter 2026 Results

Intellicheck, Inc. (IDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Intellicheck Reports Third Quarter 2026 Results Net Income Rises to $0.5 Million Adjusted EBITDA Increases to $0.9 Million Cash Balance Grows to $13.2 Million, Highest Level Since the End of 2021, with No Debt MELVILLE, NEW YORK – November 12, 2026 – Intellicheck, Inc. (Nasdaq: I

$CSTLMed

DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging

Castle Biosciences presented data on DecisionDx-Melanoma at SDPA and Dermato-Onco2026, showing the test can identify higher-risk patients with thin melanomas and provide individualized five-year recurrence-risk estimates. The studies suggest the test refines risk assessment beyond AJCC staging, aiding personalized care. According to the company, the test has been ordered over 260,000 times and is supported by extensive research.

$PRMMed

What Perimeter Solutions (PRM) Said on Its Q3 Earnings Call

Perimeter Solutions (PRM) reported Q3 earnings, highlighting strong international retardant sales and a 64.5% adjusted EBITDA margin. Specialty Products revenue rose 84% to $77.3M, but supply issues at PDI weighed on the outlook. The company generated $150.4M in free cash flow and expects to work through excess inventory by Q2 2027. PRM remains focused on acquisitions for capital allocation.

$PANLMed

Pangaea Logistics (PANL) Q3 2026 Earnings Call Transcript

Pangaea Logistics (PANL) reported Q3 2026 earnings with TCE rates averaging $20,414/day, up 31% YoY. Adjusted EBITDA was $52.4M, and operating cash flow was $57M. The company expanded its fleet and logistics platform, booking 5,040 shipping days for Q4 at a TCE of $21,423/day. PANL refinanced debt, lowering borrowing costs and simplifying its capital structure.

$PANLHighAI 8/10

What Pangaea Logistics Solutions (PANL) Said on Its Q3 Earnings Call

Pangaea Logistics Solutions (PANL) reported Q3 2026 record adjusted earnings, with adjusted EBITDA up 81% YoY to $52.4M and adjusted net income of $33.6M ($0.52 per share). Higher freight rates and Arctic shipping activity drove results. The company refinanced $145M in debt, cutting future interest expenses. Management expects firm market conditions in 2027, contingent on easing disruptions.

$CSTLMed

Castle Bio (CSTL) Q3 2026 Earnings Call Transcript

Castle Bio (CSTL) reported Q3 2026 revenue of $102.9M, up 24% YoY, driven by 47% growth in TissueCypher test volume. Net cash from operations was $19.7M, with $278M in cash and equivalents. The company raised full-year revenue guidance to $385M-$395M, up from $365M-$375M. DecisionDx-Melanoma saw 5% YoY growth, while TissueCypher is expected to grow 50%-52% for the year.